IGF-II Serum Levels Increase Discrimination Between Benign Prostatic Hyperplasia and Prostate Cancer and Improve the Predictive Value of PSA in Clinical Staging

This publication has 24 references indexed in Scilit:

• Cancer incidence and mortality in Europe, 2004
  Annals of Oncology, 2005
• Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening
  Urology, 2004
• Serum human glandular kallikrein (hK2) and insulin‐like growth factor 1 (IGF‐1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA
  The Prostate, 2002
• Plasma Insulin-Like Growth Factor-I, Insulin-Like Growth Factor-Binding Proteins, and Prostate Cancer Risk: a Prospective Study
  JNCI Journal of the National Cancer Institute, 2000
• Serum Levels of Insulin-Like Growth Factor I (IGF-I), IGF-II, IGF-Binding Protein-3, and Prostate-Specific Antigen as Predictors of Clinical Prostate Cancer
  Journal of Clinical Endocrinology & Metabolism, 2000
• Systemic Administration of Insulin-Like Growth Factor I (IGF-I) Causes Growth of the Rat Prostate
  Journal of Urology, 1997
• Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin- like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium
  Journal of Clinical Endocrinology & Metabolism, 1996
• Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: evidence for an IGF- II autocrine growth loop
  Journal of Clinical Endocrinology & Metabolism, 1995
• Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients
  Journal of Clinical Endocrinology & Metabolism, 1993
• On the statistical analysis of ROC curves
  Statistics in Medicine, 1989